Jupiter Topco LLC Invests $123.28 Million in Scholar Rock Holding Corporation $SRRK

Jupiter Topco LLC bought a new stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 2,242,106 shares of the company’s stock, valued at approximately $123,279,000. Jupiter Topco LLC owned approximately 1.84% of Scholar Rock as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Siren L.L.C. boosted its position in Scholar Rock by 17.0% in the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after buying an additional 1,575,008 shares in the last quarter. BlackRock Inc. acquired a new stake in Scholar Rock during the 2nd quarter valued at approximately $522,175,000. Redmile Group LLC increased its position in shares of Scholar Rock by 73.7% during the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock worth $445,715,000 after buying an additional 3,845,775 shares during the period. Wellington Management Group LLP raised its position in shares of Scholar Rock by 26.7% in the 4th quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock worth $253,703,000 after acquiring an additional 1,213,541 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Scholar Rock by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock worth $228,860,000 after purchasing an additional 280,538 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Scholar Rock

In other Scholar Rock news, Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.87, for a total value of $137,045.28. Following the transaction, the director owned 59,511 shares of the company’s stock, valued at approximately $3,205,857.57. The trade was a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joshua Reed sold 3,053 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the transaction, the director owned 19,518 shares of the company’s stock, valued at $1,048,897.32. This trade represents a 13.53% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 17,149 shares of company stock valued at $923,108 in the last ninety days. Insiders own 10.30% of the company’s stock.

Scholar Rock Trading Up 3.1%

Shares of SRRK stock opened at $60.04 on Thursday. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $61.76. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.02 and a current ratio of 7.02. The company has a 50-day simple moving average of $52.62 and a two-hundred day simple moving average of $48.75. The company has a market capitalization of $7.31 billion, a price-to-earnings ratio of -17.40 and a beta of 0.69.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, meeting the consensus estimate of ($0.84). During the same quarter in the previous year, the business posted ($0.98) earnings per share. Research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on SRRK shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $76.00 price target on shares of Scholar Rock in a research note on Friday, August 7th. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $56.00 to $63.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Wedbush reiterated an “outperform” rating and set a $64.00 price objective on shares of Scholar Rock in a report on Friday, August 21st. Barclays boosted their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Four equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $58.77.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).